Moderna stock pulls back after massive one-day rally: analysts weigh in
Moderna (MRNA) shares fell over 10% in premarket trading after a 177% rally on positive melanoma vaccine trial data with Merck (MRK). Merck shares also slipped over 1%. Bank of America upgraded Moderna to Neutral, raising its price target to $170, citing the potential for diversification. Merck's Buy rating was reaffirmed with a $166 target. Both companies' stocks were impacted by the trial results.
How this was made
The 30-second read
Why it matters
The data provides a new growth avenue for Moderna beyond infectious diseases, while Merck’s oncology outlook is modestly adjusted pending further efficacy data.
Market read
First disclosure of pivotal trial results creates immediate trading interest in both stocks and the broader oncology biotech sector.
What to watch
Potential manufacturing scale‑up challenges and competition from other melanoma therapies.
Background
Moderna’s intismeran vaccine, co‑developed with Merck’s Keytruda, achieved its primary endpoint in a late‑stage melanoma trial, prompting analyst upgrades and price target revisions.
Ticker impact
Moderna shares fell over 10% pre‑market after its personalized melanoma vaccine trial met its primary endpoint, a fresh clinical‑trial result.
Short‑term downside pressure with potential rebound if hazard‑ratio targets are confirmed.
First report of pivotal trial data; analyst upgraded and raised price target, indicating material new information.
Merck stock slipped ~1% as its partner Moderna announced the trial result, affecting expectations for Keytruda combination therapy.
Modest short‑term decline, possible recovery if data supports broader use.
Partner trial outcome directly impacts Merck’s oncology pipeline expectations.
Market effects
Positive oncology data may lift biotech and cancer‑therapy stocks, but uncertainty around combination efficacy tempers broad rally.
US biotech sector sees heightened activity; limited immediate effect on other regions.
Highlights mRNA platform expansion beyond infectious disease, influencing global biotech investment themes.
Counterpoint
The trial’s hazard‑ratio may be insufficient for regulatory approval; the pull‑back could signal over‑optimism.
Key entities
- CompanyModerna
Biotech firm developing mRNA‑based cancer vaccine.
- CompanyMerck
Pharma partner providing Keytruda immunotherapy.
